| Ticker: TPMC | 5265 Capital Boulevard | |
| Exchange: NASDAQ-National Market | Raleigh, North Carolina 27616 | |
| Industry: Manufacturing | (919) 876-7800 |
| Type of Shares: | Common Shares | Filing Date: | 6/7/96 | |
| U.S. Shares: | 3,000,000 | Offer Date: | 9/25/96 | |
| Non-U.S. Shares: | 0 | Filing Range: | $10.00 - $12.00 | |
| Primary Shares: | 2,400,000 | Offer Price: | $8.00 | |
| Secondary Shares: | 600,000 | Gross Spread: | $0.56 | |
| Offering Amount: | $33,000,000 | Selling: | $0.30 | |
| Expenses: | $685,000 | Reallowance: | $0.10 | |
| Shares Out After: | - |
| Manager | Tier | Phone |
| Lehman Brothers Incorporated | Lead Manager | (212) 640-6129 |
| Sands Brothers & Co., Ltd. | Co-manager | (212) 697-5200 |
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 3/31/96 | 3/31/95 | 3/31/96 | ||
| Revenue: | $1.38 | $3.66 | $0.42 | Assets: | $4.84 |
| Net Income: | -$6.97 | $1.83 | -$0.62 | Liabilities: | $2.37 |
| EPS: | Equity: | $2.46 | |||
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company manufactures medical adhesive products that can replace sutures and staples in various medical and surgical procedures. The Company's medical adhesives can be used to close and seal wounds and incisions rapidly and stop leakage of blood and other body fluids from injured tissue. The Company's nonabsorbable products can be used to replace sutures and staples for certain topical wound closure applications, while the Company's absorbable products can potentially be used as surgical sealants and surgical adhesives for internal wound closure and management. Tri-Point's medical adhesive products align injured tissue without the trauma caused by suturing or stapling and allow natural healing to proceed. In addition, Tri-Point's medical adhesive products result in lower overall procedure costs and are easier and quicker to prepare and use than sutures or staples. The worldwide market for sutures and staples for topical and internal applications is currently estimated to be 4# billion, and the Company expects that it will compete for a portion of this market. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for capital expenditures, clinical trials, research and development and for other general corporate purposes. |
©1996 IPO Data Systems, Inc. - All rights reserved.